Priority Lists
Protocol Posting of
Activations
Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors
| Study Coordinator(s) | Richard I. Fisher, M.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Pathologists, NCORP |
A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days X 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma.
| Study Coordinator(s) | Carolyn M. Johnston, M.D. |
| Participants | Members, NCORP |
Randomized Phase III Trial of Carboplatin and Paclitaxel plus Tirapazamine versus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer Cisplatin, Paclitaxel, Tirapazamine vs. Cisplatin, Paclitaxel Specimen submission per S9925
| Study Coordinator(s) | Stephen K. Williamson, M.D., Primo N. Lara, Jr., M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, EPP, CTSU |
Closures
Study of ProMACE-CytaBOM with Trimethoprim Sulfamethoxazole, Granulocyte Colony Stimulating Factor (G-CSF) and Antiretroviral Therapy in Patients with AIDS Related Lymphoma, Phase II
| Study Coordinator(s) | Ellen R. Gaynor, M.D., Lode J. Swinnen, M.D., Anne R. McCall, M.D. |
| Participants | Members, Medical Oncologists, NCORP |
| Closure Date | 2000-12-01 |
Induction Chemotherapy Followed by Chemoradiation for Organ Preservation in Patients with Advanced Resectable Cancer of the Hypopharynx and Base of Tongue, Phase II
| Study Coordinator(s) | S.G. Urba, M.D., Steven C. Marks, M.D., P.G. Shankar Giri, M.D., David J. Adelstein, M.D. |
| Closure Date | 2001-12-01 |
Amendments, Revisions, Memoranda
A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Agressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT.
| Study Coordinator(s) | David G. Maloney, M.D.,Ph.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Clonal Hematopoiesis as a Marker of Genetic Damage Pilot Study Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence, Ancillary to S9623
| Study Coordinator(s) | Marilyn L. Slovak, Ph.D., Cheryl L. Willman, M.D., Wendy Stock, M.D. |
| Participants | Medical Oncologists, Pathologists, NCORP, Members |
A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients with Advanced Stage Poor Prognosis Hodgkin’s Disease as Defined by the International Prognostic Factors Project on Advanced Hodgkin’s Disease, Intergroup
| Study Coordinator(s) | Ellen R. Gaynor, M.D., Stephen J. Forman, M.D., Thomas M. Grogan, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, ECOG, CALGB, NCORP |
Phase II Trial of Paclitaxel, Carboplatin and Topotecan with G-CSF in Untreated Patients with Extensive Small Cell Lung Cancer
| Study Coordinator(s) | Frank R. Dunphy II, M.D., Paul J. Hesketh, M.D. |
| Participants | Members, Medical Oncologists, NCORP |
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required